117 related articles for article (PubMed ID: 21986369)
1. In vitro characteristics of 1-phenyl-3-methyl-4-acylpyrazol-5-ones iron chelators.
Filipský T; Mladěnka P; Macáková K; Hrdina R; Saso L; Marchetti F; Pettinari C
Biochimie; 2012 Jan; 94(1):125-31. PubMed ID: 21986369
[TBL] [Abstract][Full Text] [Related]
2. Effect of novel 1-phenyl-3-methyl-4-acylpyrazolones on iron chelation and Fenton reaction.
Filipský T; Mladenka P; Macáková K; Hrdina R; Saso L; Marchetti F; Pettinari C
Free Radic Biol Med; 2014 Oct; 75 Suppl 1():S29-30. PubMed ID: 26461329
[TBL] [Abstract][Full Text] [Related]
3. In vitro interactions of coumarins with iron.
Mladenka P; Macáková K; Zatloukalová L; Reháková Z; Singh BK; Prasad AK; Parmar VS; Jahodár L; Hrdina R; Saso L
Biochimie; 2010 Sep; 92(9):1108-14. PubMed ID: 20381579
[TBL] [Abstract][Full Text] [Related]
4. New synthetic approach and iron chelating studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones.
Kontoghiorghes GJ; Sheppard L; Chambers S
Arzneimittelforschung; 1987 Oct; 37(10):1099-102. PubMed ID: 3435580
[TBL] [Abstract][Full Text] [Related]
5. Fenton chemistry and iron chelation under physiologically relevant conditions: Electrochemistry and kinetics.
Merkofer M; Kissner R; Hider RC; Brunk UT; Koppenol WH
Chem Res Toxicol; 2006 Oct; 19(10):1263-9. PubMed ID: 17040095
[TBL] [Abstract][Full Text] [Related]
6. Acyclonucleoside iron chelators of 1-(2-hydroxyethoxy)methyl-2-alkyl-3-hydroxy-4-pyridinones: potential oral iron chelation therapeutics.
Liu G; Men P; Kenner GH; Miller SC; Bruenger FW
Nucleosides Nucleotides Nucleic Acids; 2004; 23(3):599-611. PubMed ID: 15113026
[TBL] [Abstract][Full Text] [Related]
7. Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
Liu J; Obando D; Schipanski LG; Groebler LK; Witting PK; Kalinowski DS; Richardson DR; Codd R
J Med Chem; 2010 Feb; 53(3):1370-82. PubMed ID: 20041672
[TBL] [Abstract][Full Text] [Related]
8. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
9. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
Chaston TB; Richardson DR
Am J Hematol; 2003 Jul; 73(3):200-10. PubMed ID: 12827659
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and iron(III)-chelating properties of novel 3-hydroxypyridin-4-one hexadentate ligand-containing copolymers.
Zhou T; Kong XL; Liu ZD; Liu DY; Hider RC
Biomacromolecules; 2008 May; 9(5):1372-80. PubMed ID: 18373358
[TBL] [Abstract][Full Text] [Related]
11. Iron autoxidation and free radical generation: effects of buffers, ligands, and chelators.
Welch KD; Davis TZ; Aust SD
Arch Biochem Biophys; 2002 Jan; 397(2):360-9. PubMed ID: 11795895
[TBL] [Abstract][Full Text] [Related]
12. A comparison of bathophenanthrolinedisulfonic acid and ferrozine as chelators of iron(II) in reduction reactions.
Cowart RE; Singleton FL; Hind JS
Anal Biochem; 1993 May; 211(1):151-5. PubMed ID: 8323027
[TBL] [Abstract][Full Text] [Related]
13. Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation.
Le NT; Richardson DR
Carcinogenesis; 2003 Jun; 24(6):1045-58. PubMed ID: 12807743
[TBL] [Abstract][Full Text] [Related]
14. Iron chelation, quo vadis?
Nick H
Curr Opin Chem Biol; 2007 Aug; 11(4):419-23. PubMed ID: 17644021
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.
Kalinowski DS; Yu Y; Sharpe PC; Islam M; Liao YT; Lovejoy DB; Kumar N; Bernhardt PV; Richardson DR
J Med Chem; 2007 Jul; 50(15):3716-29. PubMed ID: 17602603
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.
Bendova P; Mackova E; Haskova P; Vavrova A; Jirkovsky E; Sterba M; Popelova O; Kalinowski DS; Kovarikova P; Vavrova K; Richardson DR; Simunek T
Chem Res Toxicol; 2010 Jun; 23(6):1105-14. PubMed ID: 20521781
[TBL] [Abstract][Full Text] [Related]
17. In vitro analysis of iron chelating activity of flavonoids.
Mladěnka P; Macáková K; Filipský T; Zatloukalová L; Jahodář L; Bovicelli P; Silvestri IP; Hrdina R; Saso L
J Inorg Biochem; 2011 May; 105(5):693-701. PubMed ID: 21450273
[TBL] [Abstract][Full Text] [Related]
18. Ferric and cupric reductase activities by iron-limited cells of the green alga Chlorella kessleri: quantification via oxygen electrode.
Weger HG; Walker CN; Fink MB
Physiol Plant; 2007 Oct; 131(2):322-31. PubMed ID: 18251903
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro trypanocidal activity of some novel iron chelating agents.
Singh PK; Jones MM; Lane JE; Nesset A; Zimmerman LJ; Ribeiro-Rodrigues R; Richter A; Stenger MR; Carter CE
Arzneimittelforschung; 1997 Mar; 47(3):311-5. PubMed ID: 9105552
[TBL] [Abstract][Full Text] [Related]
20. Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy.
Bernhardt PV; Chin P; Richardson DR
J Biol Inorg Chem; 2001 Oct; 6(8):801-9. PubMed ID: 11713687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
